<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682420</url>
  </required_header>
  <id_info>
    <org_study_id>CD-0018</org_study_id>
    <nct_id>NCT02682420</nct_id>
  </id_info>
  <brief_title>everlinQ endoAVF Post Market Study</brief_title>
  <official_title>everlinQ endoAVF Post Market Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TVA Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TVA Medical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center study to evaluate the everlinQ endoAVF System when used to create
      an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for
      hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency - time to first intervention to maintain patency</measure>
    <time_frame>endoAVF creation to intervention up to 12 months</time_frame>
    <description>Time of successful endoAVF creation until any intervention designed to maintain or reestablish patency or loss of endoAVF patency</description>
  </primary_outcome>
  <other_outcome>
    <measure>Time from endoAVF creation to complete abandonment (Secondary Patency)</measure>
    <time_frame>endoAVF creation to abandonment up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to Endovascular Fistula (endoAVF) Maturation (Vascular Access Useability)</measure>
    <time_frame>endoAVF creation to usability measured up to 52 weeks</time_frame>
    <description>Total time (number of days) from successful endoAVF creation to one of the following:
Successful hemodialysis using 2 needle cannulation
Vascular accesses that is free of stenosis or thrombosis, measured via duplex ultrasound</description>
  </other_outcome>
  <other_outcome>
    <measure>Intervention Rate</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>any intervention required to a) maintain or re-establish patency (fistula is free of thrombosis) of vascular access or b) assist to develop maturation of endoAVF</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>endoAVF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>everlinQ endoAVF System</intervention_name>
    <arm_group_label>endoAVF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (age &gt;18 years old)

          -  Currently on chronic dialysis or expected to be started on chronic dialysis within 3
             months of planned endoAVF creation

          -  Target treatment vein diameter(s) for fistula creation ≥ 2.0 mm as measured via Duplex
             Ultrasound or Venogram

          -  Target treatment artery diameter(s) for fistula creation ≥ 2.0 mm as measured via
             Duplex Ultrasound or Arteriogram

          -  Both radial and ulnar artery flow to the hand, as confirmed with Duplex Ultrasound
             and/or Allen's test (i.e.: palmar arch)

        Exclusion Criteria:

          -  Known central venous stenosis or central vein narrowing &gt; 50% based on imaging on the
             same side as the planned AVF creation

          -  Absence of perforator feeding the target cannulation vein(s) via Venogram

          -  Occlusion or stenosis &gt;50% of target cannulation cephalic or basilic vein

          -  Significantly compromised (≥50% stenosis) flow in the treatment arm

          -  Documented ejection fraction (EF) ≤35% in the last 6 months

          -  Pregnant women

          -  New York Heart Association (NYHA) class III or IV heart failure

          -  Hypercoagulable state

          -  Known bleeding diathesis

          -  Documented history of drug abuse including intravenous drugs within six months of AVF
             creation

          -  &quot;Planned&quot; concomitant major surgical procedure within 6 months of enrollment or
             previous major surgery within 30 days of enrollment

          -  Known allergy to contrast dye which cannot be adequately pre-medicated

          -  Known adverse effects to sedation and/or anesthesia which cannot be adequately
             pre-medicated

          -  Evidence of active infections on the day of the index procedure

          -  Estimated life expectancy &lt; 1 year

          -  Patient is not willing to provide written informed consent, is not geographically
             stable and/or not willing to comply with required follow-up

          -  Patient with a target cannulation vein that is &gt; 6mm deep that would require a
             transposition procedure, defined as the elevation of a target cannulation vein AND the
             creation of a new AV fistula

          -  Patient is not willing to undergo a 2nd stage procedure as defined in Section 4.5.3 of
             the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Inston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Birmingham NHS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Schmitz-Rixen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univerisity of Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Health Care Society</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dominikus Hospital</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals - NHS Foundation Trust</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's University</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

